Two Sigma Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-77,200
| Closed | -$143K | – | 3431 |
|
|
2023
Q1 | $143K | Buy |
77,200
+24,384
| +46% | +$30.2K | ﹤0.01% | 2620 |
|
|
2022
Q4 | $58.6K | Sell |
52,816
-44,158
| -46% | -$62.9K | ﹤0.01% | 2576 |
|
|
2022
Q3 | $227K | Sell |
96,974
-36,111
| -27% | -$128K | ﹤0.01% | 2066 |
|
|
2022
Q2 | $403K | Buy |
133,085
+67,947
| +104% | +$330K | ﹤0.01% | 1903 |
|
|
2022
Q1 | $442K | Sell |
65,138
-253,413
| -80% | -$1.81M | ﹤0.01% | 2081 |
|
|
2021
Q4 | $2.66M | Buy |
318,551
+95,648
| +43% | +$788K | 0.01% | 1668 |
|
|
2021
Q3 | $1.66M | Sell |
222,903
-74,726
| -25% | -$463K | ﹤0.01% | 2161 |
|
|
2021
Q2 | $2.02M | Buy |
297,629
+202,780
| +214% | +$1.68M | ﹤0.01% | 1853 |
|
|
2021
Q1 | $974K | Buy |
+94,849
| New | +$1.04M | ﹤0.01% | 2350 |
|
|
2020
Q1 | – | Sell |
-123,919
| Closed | -$1.08M | – | 4009 |
|
|
2019
Q4 | $1.08M | Buy |
123,919
+68,058
| +122% | +$368K | ﹤0.01% | 2109 |
|
|
2019
Q3 | $186K | Sell |
55,861
-39,273
| -41% | -$157K | ﹤0.01% | 3208 |
|
|
2019
Q2 | $471K | Sell |
95,134
-100,124
| -51% | -$532K | ﹤0.01% | 2541 |
|
|
2019
Q1 | $1.21M | Sell |
195,258
-206,674
| -51% | -$999K | ﹤0.01% | 1711 |
|
|
2018
Q4 | $1.35M | Buy |
401,932
+80,863
| +25% | +$378K | 0.01% | 1457 |
|
|
2018
Q3 | $2.09M | Buy |
321,069
+117,840
| +58% | +$876K | 0.01% | 1454 |
|
|
2018
Q2 | $1.56M | Buy |
+203,229
| New | +$2.93M | ﹤0.01% | 1810 |
|
Other funds holding JNCE
Two Sigma Investments's JNCE Position: Q2 2023 in Review
Two Sigma Investments sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 77,200 shares — an estimated $143K sold.
Two Sigma Investments first reported a position in JNCE in Q2 2018 and held it in 16 quarters. The position peaked at $2.66M in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Two Sigma Investments reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Two Sigma Investments sold 77,200 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $143K.
- Two Sigma Investments first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 16 quarters.
- Two Sigma Investments's Jounce Therapeutics, Inc. Common Stock position peaked at $2.66M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Two Sigma Investments's 13F filing for Q2 2023, filed 14 Aug 2023.